Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study

Emerg Microbes Infect. 2022 Dec;11(1):2680-2688. doi: 10.1080/22221751.2022.2133639.

Abstract

The long-term effect of coronavirus disease 2019 (COVID-19) has been rarely known. This study aimed to investigate healthy outcomes of COVID-19 survivors up to 2 years after the infection. A total of 155 COVID-19 patients, who were discharged from Shenzhen Third People's Hospital from February 2020 to April 2020, were enrolled and followed up until March 4, 2022. COVID-19 survivors received questionnaires of long COVID symptoms and psychological symptoms, pulmonary function tests, chest computed tomography (CT) scans and routine laboratory tests. Two years after infection, 36.6% of patients had at least one symptom of long COVID. Vision impairment and fatigue were the most common symptom. 35.0% of participants still had at least one psychological symptom of anxiety, depression, post-traumatic stress symptoms, and sleep difficulties. Radiographic abnormalities were presented in 50.7% of patients, with the most common features of fibrosis-like lesions and residual ground-glass opacity. Diffuse dysfunction (24.0%) was the main abnormalities of pulmonary function tests. Most laboratory parameters returned to normal range, while persistent abnormalities in kidney and liver function test were observed in a subset of participants after discharge. Two years after COVID-19 infection, persistent symptoms of long COVID and psychological symptoms, as well as abnormalities in pulmonary function tests and CT, were still common in a subset of recovering individuals. These findings were limited by the lack of a healthy control group and pre-COVID assessments, which should be confirmed by further large-scale studies.

Keywords: COVID-19; SARS-CoV-2; follow-up; long COVID; risk factor.

MeSH terms

  • COVID-19 Testing
  • COVID-19*
  • Humans
  • Lung / diagnostic imaging
  • Post-Acute COVID-19 Syndrome
  • Prospective Studies
  • SARS-CoV-2

Grants and funding

This study was supported by the National Science Fund for Distinguished Young Scholars [grant number 82025022], the Central Charity Fund of Chinese Academy of Medical Science [grant number 2020-PT310-009], the Emergency Grants for Prevention and Control of SARS-CoV-2 of Guangdong Province [grant number 2022A1111090001], the Science and Technology Innovation Committee of Shenzhen Municipality [grant number JSGG20200207155251653], [grant number JSGG20220226090002003], [grant number JCYJ20190809160213289], and the Emergency Key Program of Guangzhou Laboratory [grant number EKPG21-29].